Compare BridgeBio Pharma Inc (BBIO) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Okta, Inc. — how do they compare? BridgeBio Pharma Inc trades at $82.09 (market cap $16.46B), while Okta, Inc. trades at $149.89 (market cap $26.87B). The key difference: Okta, Inc. is the larger of the two by market cap, and Okta, Inc. is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | OKTA | |
|---|---|---|
Market Cap | $16.46B | $26.87B |
Sector | Health | Technology |
52-Week High | $90.17 | $154.62 |
52-Week Low | $44.81 | $62.93 |
Enterprise Value | $18.02B | $24.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
OKTA trades at $139.53, up 0.65% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.91 exceeding the $0.853 estimate. Revenue grew to $2.61 billion in 2025, and net income turned positive at $28 million. Analyst sentiment is positive, with 72.55% recommending Buy.
The outlook is favorable due to AI-driven demand for cybersecurity, but high valuation multiples pose risks. The stock faces competition and must sustain growth to justify its P/E of 101.11. Upside exists if earnings continue to beat expectations, yet volatility from market sentiment shifts is a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
